ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

NEXT STORY
Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology
PREV STORY
Small Retail Pharmacies likely targets of Larger Chains in Malaysia Retail Pharmacy Market: Ken Research
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Conclusion of an Agreement in Principle Between Bold Capital and Dymedso, a Corporation Involved in Lung Disease Treatment and Treating COVID-19 Pulmonary Issues

author_avatar
NASDAQ Market News

Kezar Announces Presentations During Upcoming Scientific Conferences

author_avatar
NASDAQ Market News

Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

author_avatar
NASDAQ Market News